Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Sarcoma 5Neoplasms 5Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1MSI-H or dMMR Advanced Solid Tumors 1Lung Neoplasms 1Leiomyosarcoma 1Gynecological Cancer 1Gastrointestinal Stromal Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Fallopian Tube Neoplasms 1Extensive Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1

Interventions

Imatinib Mesylate 26Sunitinib 22nilotinib 12ripretinib 11regorafenib 7avapritinib 7tanespimycin 2pexidartinib 2masitinib 2famitinib 2Midazolam 2IDRX-42 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2umbralisib 1trastuzumab deruxtecan 1trametinib 1tinostamustine 1spartalizumab 1ribociclib 1repaglinide 1ponatinib 1perifosine 1pembrolizumab 1olverembatinib 1olaratumab 1motesanib diphosphate 1dabrafenib 1cediranib 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Stromal Tumors × anlotinib × Clear all
NCT04106024 2019-09-26

Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

Cttq

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡